Search results for "CyclinE"

showing 10 items of 194 documents

Ten-Year Safety and Efficacy Analyses of the Big 02-98 Phase III Trial with an Exploratory Analysis on the Role of Ki67 in Predicting Benefit of Adju…

2014

ABSTRACT Aim: The BIG 2-98 is a randomized phase III trial that tested the effect of adding docetaxel with anthracycline-based adjuvant chemotherapy (CT) in women with node-positive breast cancer (BC). here we present the 10 year safety and efficacy analyses and report an exploratory analysis of the predictive value of Ki67 for docetaxel efficacy. Methods: In total, 2,887 patients with node positive BC were randomly assigned to one of four treatments: (I) sequential control: doxorubicin (A, 75 mg/m2) × 4 → CMF; (II) concurrent control: AC × 4 → CMF; (III) A × 3 → docetaxel (T, 100 mg/m2) × 3 → CMF and (IV) : AT (50/75 mg/m2) × 4 → CMF. The primary objective was to evaluate the efficacy of d…

Oncologymedicine.medical_specialtyAspirinAnthracyclineProliferation indexAdjuvant chemotherapybusiness.industrymedicine.medical_treatmentHematologyExploratory analysismedicine.diseaseSurgeryBreast cancerOncologyDocetaxelInternal medicinemedicinebusinessAdjuvantmedicine.drugAnnals of Oncology
researchProduct

Use of myocardial work for multiparametric detection of subclinical anthracycline cardiotoxicity in breast cancer patients

2021

Abstract Funding Acknowledgements Type of funding sources: None. Background The aim of our study was to assess subclinical cardiac effects of anthracyclines (ANTs) in women treated for breast cancer (BC). Methods We enrolled 46 female patients with BC undergoing adjuvant treatment with anthracycline-containing chemotherapy (CT) followed by taxane (paclitaxel/docetaxel).  Patients underwent physical examination, electrocardiogram (ECG) and standard transthoracic echocardiography (TTE) including evaluation of diastolic and systolic function, measured as left ventricular ejection fraction (LVEF), left ventricular global longitudinal strain (GLS) and myocardial work (MW) expressed as global wor…

Oncologymedicine.medical_specialtyCardiotoxicityEjection fractionAnthracyclinebusiness.industryGeneral Medicinemedicine.diseaseChemotherapy regimenBreast cancerDocetaxelInternal medicinemedicineRadiology Nuclear Medicine and imagingCardiology and Cardiovascular MedicineAdverse effectbusinessSubclinical infectionmedicine.drugEuropean Heart Journal - Cardiovascular Imaging
researchProduct

PKP-020 Impact of nadph oxidase functional polymorphisms in acute myeloid leukaemia induction chemotherapy

2016

Background NADPH oxidase, a key mediator of oxidative cardiac damage and remodelling, modulates anthracycline clinical cardiotoxicity. Purpose Single nucleotide polymorphisms (SNPs) of NADPH oxidase genes could lead to interindividual differences in treatment outcome in acute myeloid leukaemia (AML) patients. Material and methods The main three NADPH oxidase polymorphisms (CYBA:rs4673, NCF4:rs1883112 and RAC2:rs13058338) were evaluated in 225 adult patients at the initial diagnosis of AML using a mass spectrometry based multiplex genotyping assay (Sequenom). All patients received induction chemotherapy consisting of idarubicin plus cytarabine (PETHEMA 99, 2007 and 2010 trials). The efficacy…

Oncologymedicine.medical_specialtyCardiotoxicityNADPH oxidasebiologyAnthracyclinebusiness.industryInduction chemotherapySingle-nucleotide polymorphismInternal medicineGenotypeImmunologymedicinebiology.proteinCytarabineIdarubicinGeneral Pharmacology Toxicology and Pharmaceuticsbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Hematopoietic Stem Cell Transplantation in APL

2018

The indication for hematopoietic stem cell transplant (HSCT) in APL has evolved historically from a widespread use in frontline therapy during the pre-ATRA era to a virtual rejection of this indication when patients are treated with modern treatments containing all-trans retinoic acid (ATRA), either in combination with chemotherapy, arsenic trioxide (ATO), or both. This indication has gradually been abandoned and explicitly rejected by the European LeukemiaNet recommendations. The high cure rate obtained using ATRA plus chemotherapy or ATRA plus ATO indicates that there is no role for HSCT for patients who achieve molecular remission at the end of consolidation. The HSCT in first complete r…

Oncologymedicine.medical_specialtyChemotherapyAnthracyclinebusiness.industrymedicine.medical_treatmentSalvage therapyHematopoietic stem cellHematopoietic stem cell transplantationMinimal residual diseaseEuropean LeukemiaNetsurgical procedures operativemedicine.anatomical_structureimmune system diseasesInternal medicinemedicineCytarabinebusinessmedicine.drug
researchProduct

A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute …

2015

The polymorphism rs16754 of the WT1 gene has been described as a possible prognostic marker in different acute myeloid leukemia (AML) cohorts; however, it is not supported by all the studies. We performed the first meta-analysis evaluating the effect of this polymorphism upon the effectiveness of standard AML therapy. Fourteen cohort studies were included (3618 patients). Patients with the variant allele showed a significant higher overall survival (OS) at 5 years (OR: 1.24, 95% CI: 1.06-1.45, P = 0.007, with dominant model). WT1 did not influence complete remission, but a higher disease-free survival was observed with the variant allele. In the subgroup analysis, Caucasians, pediatric and …

Oncologymedicine.medical_specialtySubgroup analysisPolymorphism Single NucleotideCohort Studies03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineHumansIdarubicinAnthracyclinesWT1 ProteinsGenetic Association StudiesEtoposideSurvival analysisEtoposidePharmacologybusiness.industryCytarabineMyeloid leukemiaSurvival AnalysisLeukemia Myeloid AcuteObservational Studies as Topic030220 oncology & carcinogenesisMeta-analysisImmunologyCytarabineMolecular Medicinebusiness030215 immunologymedicine.drugCohort studyThe Pharmacogenomics Journal
researchProduct

A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthr…

2012

Abstract Abstract 46 Background Elacytarabine, a fatty acid derivative (elaidic acid ester) of cytarabine, has pharmacokinetic and pharmacodynamic properties that may lead to improved clinical outcomes (Adema et al., 2011) compared to cytarabine. A phase I study had established 1000 mg/m2/d continuous infusion on d 1 – 5 as a safe and effective dose of elacytarabine given in combination with idarubicin at 12 mg/m2/d IV d 1 – 3 (Giles et al., 2012). Mechanism of Action The mechanism of action is similar to cytarabine, but unlike cytarabine, plasma elimination half-life is long, intracellular distribution is prolonged and activity is independent of membrane nucleoside transporters. Resistance…

Oncologymedicine.medical_specialtyeducation.field_of_studyCombination therapyAnthracyclineElacytarabinebusiness.industryImmunologyPopulationPhases of clinical researchCell BiologyHematologyPharmacologyBiochemistryRegimenInternal medicineCytarabineMedicineIdarubicinbusinesseducationmedicine.drugBlood
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct

The Wnt/beta-Catenin Pathway Attenuates Experimental Allergic Airway Disease

2014

Abstract Signaling via the Wnt/β-catenin pathway plays crucial roles in embryogenesis and homeostasis of adult tissues. In the lung, the canonical Wnt/β-catenin pathway has been implicated in remodeling processes, development of emphysema, and fibrosis. However, its relevance for the modulation of allergic responses in the lung remains unclear. Using genetically modified mice with lung-specific inducible (doxycycline) Wnt-1 expression (CCSP-rtTA × tetO-Wnt1), the impact of Wnt on the development of allergic airway disease was analyzed. Overexpression of Wnt during the allergen challenge phase attenuated the development of airway inflammation in an acute model, as well as in a more therapeut…

OvalbuminTransgeneT cellT-LymphocytesImmunologyMice TransgenicWnt1 ProteinMiceAdjuvants ImmunologicFibrosisCell MovementmedicineRespiratory HypersensitivityImmunology and AllergyAnimalsLungCells Culturedbeta CateninMice Inbred BALB CLungbusiness.industryWnt signaling pathwayDendritic Cellsrespiratory systemmedicine.diseaseFlow CytometryIn vitroCoculture Techniquesrespiratory tract diseasesMice Inbred C57BLmedicine.anatomical_structureCateninDoxycyclineImmunologyCytokinesbusinessLithium ChlorideHomeostasisSignal Transduction
researchProduct

Non-surgical management of chronic periodontitis with two local drug delivery agents-A comparative study

2011

Background: The selective removal or inhibition of pathogenic microbes with locally delivered antimicrobials when combined with scaling and root planing is often an effective approach for the managment of chronic periodontitis. Aim: To compare the clinical efficacy of tetracycline fibers and a xanthan based chlorhexidine gel in the treatment of chronic periodontitis. Methods and materials: Thirty systemically healthy patients in the age group of 30-50 years suffering from generalized chronic moderate periodontitis were selected. For each subject, two experimental sites were chosen that had probing depth >5mm and were located in symmetric quadrants and the sites were randomized at split mout…

PeriodontitisChlorhexidine gelbusiness.industryTetracyclineChlorhexidineDentistryOdontología:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseChronic periodontitisCiencias de la saludScaling and root planingDrug deliveryUNESCO::CIENCIAS MÉDICASmedicineClinical efficacybusinessGeneral Dentistrymedicine.drug
researchProduct

INFLUENCE OF α-6-DEOXY-5-OXYTETRACYCLINE ON SOME PHARMA-COLOGICAL CHARACTERISTICS OF DAUNOMYCIN

1973

(1) Treatment with doxycyline substantially reduces the acute toxicity of daunomycin to the mouse. Treatment with doxycycline alters the distribution of daunomycin amongst the body tissues of the mouse. The ability of the isolated kidney to bind the daunomycin is enhanced by pretreatment with doxycycline. This observation is in agreement with the phenomenon noted in vivo with the same organ. (2) The antineoplastic activity of daunomycin, tested in vivo in mice bearing Sarcoma 180 is not modified by treatment with doxycyctine, nor does doxycycline modify the inhibition of DNA synthesis in isolated Sarcoma 180 cells by daunomycin. (3) The experiments carried out on isolated cell, namely: (a) …

PharmacologyDoxycyclineDNA synthesisOxytetracyclinePharmacologyBiologyAcute toxicitychemistry.chemical_compoundchemistryIn vivoDrug DiscoverymedicineDistribution (pharmacology)ThymidineReceptormedicine.drugThe Journal of Antibiotics
researchProduct